Precision medicines for B-cell leukaemias and lymphomas; progress and potential pitfalls.
about
Breaking good: the inexorable rise of BTK inhibitors in the treatment of chronic lymphocytic leukaemia.Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia.Paradoxical activation of alternative pro-survival pathways determines resistance to MEK inhibitors in chronic lymphocytic leukaemia.
P2860
Precision medicines for B-cell leukaemias and lymphomas; progress and potential pitfalls.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Precision medicines for B-cell leukaemias and lymphomas; progress and potential pitfalls.
@en
Precision medicines for B-cell leukaemias and lymphomas; progress and potential pitfalls.
@nl
type
label
Precision medicines for B-cell leukaemias and lymphomas; progress and potential pitfalls.
@en
Precision medicines for B-cell leukaemias and lymphomas; progress and potential pitfalls.
@nl
prefLabel
Precision medicines for B-cell leukaemias and lymphomas; progress and potential pitfalls.
@en
Precision medicines for B-cell leukaemias and lymphomas; progress and potential pitfalls.
@nl
P2093
P2860
P356
P1476
Precision medicines for B-cell leukaemias and lymphomas; progress and potential pitfalls.
@en
P2093
Catrin Pritchard
Jesvin Samuel
Martin J S Dyer
Meike Vogler
Salvador Macip
Sandrine Jayne
P2860
P304
P356
10.1111/BJH.12219
P407
P577
2013-01-24T00:00:00Z